MedTrace Logo

Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish Study of Feasibility, Costs, and Implementation

NCT07802015 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-09-03

No results posted yet for this study

Summary

The goal of this observational multicenter feasibility and implementation study is to evaluate home-based treatment with intravenous Cytarabine for patients with acute myeloid leukemia in Denmark. The study aims to generate research-based evidence on feasibility, safety, patient impact, health economic costs, and implementation of home-based intravenous chemotherapy treatment.

The main questions it aims to answer are:

1\. What is the existing evidence on home-based chemotherapy treatment for patients with hematological malignancies, including feasibility, safety, symptoms, quality of life, and cost-effectiveness?

2\. Is home-based treatment with intravenous Cytarabine feasible and safe for patients with acute myeloid leukemia in Denmark?

3\. What are the costs, patient-reported outcomes, and caregiver roles related to home-based Cytarabine treatment?

4\. What are the key barriers and facilitators experienced by patients, caregivers, and healthcare professionals during home-based Cytarabine treatment? Which national strategies and recommendations can support the implementation, scalability, sustainability, and equitable access to home-based intravenous Cytarabine treatment across healthcare settings in Denmark?

Conditions

  • Hematologic Cancer
  • Acute Myeloid Leukaemia (AML)
  • Hospital At Home
  • Home-based Chemotherapy

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Kristina Holmegaard Nørskov, PhD, Assoc. Prof. · University of Southern Denmark & Zealand University Hospital

  • Christian Landbo, MSc Global Health · University of Southern Denmark & Zealand University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-17
Primary Completion
2027-12-30
Completion
2029-01-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07802015 on ClinicalTrials.gov